Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0035-9203(89)90685-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Transcriptomic Profiling and Tumor Microenvironment Classification Reveal Unique and Dynamic Immune Biology in HIV-Associated Kaposi Sarcoma.
Cells
January 2025
Department of Oncology (Medical Oncology), Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Kaposi Sarcoma (KS) is a vascular tumor originating from endothelial cells and is associated with human herpesvirus 8 (KSHV) infection. It disproportionately affects populations facing health disparities. Although antiretroviral therapy (ART) has improved KS control in people with HIV (PWH), treatment options for advanced KS remain limited.
View Article and Find Full Text PDFHIV-1 Viremia and Cancer Risk in 2.8 Million People: the South African HIV Cancer Match Study.
Clin Infect Dis
December 2024
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Background: Most research on HIV-1 viremia and cancer risk is from high-income countries. We evaluated the association between HIV-1 viremia and the risk of various cancer types among people with HIV (PWH) in South Africa.
Methods: We analysed data from the South African HIV Cancer Match study, based on laboratory measurements from the National Health Laboratory Services and cancer records from the National Cancer Registry from 2004-2014.
Prevalence of Kaposi sarcoma in the United States: SEER cross-sectional study.
Proc (Bayl Univ Med Cent)
December 2024
Cullen College of Engineering, University of Houston, Houston, Texas, USA.
Primary Kaposi sarcoma (KS) is a rare cancer caused by human herpesvirus-8 that most often affects people with compromised immune systems. Since knowledge of the relationship between disease and sociodemographic factors contributes to the development of precision medicine, we investigated the prevalence of KS within the US population. Using SEER, we found that the Black population had the highest prevalence rate in 2018 compared to other racial groups.
View Article and Find Full Text PDFIncreased human herpesvirus-8 neutralizing response during remission from Kaposi's sarcoma.
J Gen Virol
November 2024
Institute of Clinical and Molecular Virology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, Schlossplatz 1, D-91054 Erlangen, Germany.
Article Synopsis
- - Human herpesvirus-8 (HHV-8), linked to Kaposi's sarcoma (KS), is more prevalent in individuals co-infected with HIV-1, especially in sub-Saharan African men, making it common among this group prior to the HIV-1 epidemic.
- - Researchers tested 58 HHV-8-positive serum samples for antibodies targeting specific glycoproteins and found that neutralizing capacity increases during KS remission, with heightened antibodies against glycoprotein K8.1 during both active disease and remission.
- - The study suggests that glycoproteins like gHgL could be key targets for neutralizing antibodies, and recovery from KS might be linked to enhanced neutralizing capacity, indicating a
Early Changes in Health-Related Quality of Life as a Biomarker of Survival in African Patients with HIV-Associated Kaposi Sarcoma.
Trop Med Infect Dis
October 2024
Department of Dermatology, University of Kwa-Zulu Natal, Durban 4001, South Africa.
Sub-Saharan Africa bears the largest public health burden of Kaposi sarcoma (KS), a leading cause of cancer mortality. Quality of life (QOL) assessments in cancer patients can provide information on prognosis beyond traditional biomarkers or biological measures. The prognostic value of QOL measures in patients with HIV-KS was evaluated.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!